Medesis Pharma SA (ALMDP) — Working Capital to Net Assets Ratio
Medesis Pharma SA (ALMDP) has a Working Capital to Net Assets ratio of 40.6% as of June 2024. Working capital of €-2.07 Million (current assets of €1.74 Million minus current liabilities of €3.81 Million) is measured against net assets of €-5.10 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Medesis Pharma SA Working Capital to Net Assets (2018–2023)
This chart shows how Medesis Pharma SA's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2018 to 2023. As of June 2024, the ratio stands at 40.6%, reflecting working capital of €-2.07 Million against net assets of €-5.10 Million EUR. See Medesis Pharma SA (ALMDP) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Medesis Pharma SA (2018–2023)
The table below presents the year-by-year Working Capital to Net Assets ratio for Medesis Pharma SA from 2018 to 2023, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Medesis Pharma SA total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 56.0% | €-2.52 Million | €-4.50 Million | €1.53 Million | €4.05 Million | ▲ +2.8 pp |
| 2022 | 53.2% | €-562.37K | €-1.06 Million | €1.37 Million | €1.93 Million | ▼ -72.7 pp |
| 2021 | 125.9% | €2.07 Million | €1.65 Million | €3.79 Million | €1.72 Million | ▲ +58.9 pp |
| 2020 | 67.0% | €-1.40 Million | €-2.08 Million | €590.59K | €1.99 Million | ▲ +63.3 pp |
| 2019 | 3.7% | €-90.00K | €-2.42 Million | €431.00K | €521.00K | ▼ -10.8 pp |
| 2018 | 14.5% | €-127.00K | €-876.00K | €440.00K | €567.00K | — |